Anti-IL-4,13 strategy in management of comormid patients in the regional register of severe bronchial asthma
Authors:
- Veronika V. NaumovaVNVeronika V. Naumova
- Darina V. KiselevaDKDarina V. Kiseleva
- Evgeny K. BeltyukovEBEvgeny K. Beltyukov
- Yana R. StarikovaYSYana R. Starikova
Open Access
- 5 December 2022
- journal article
- research article
- Published by Farmarus Print Media in Russian Journal of Allergy
- Vol. 19 (4) , 435-446
Abstract
BACKGROUND: T2 inflammation underlies bronchial asthma and inflammatory nasal diseases, supporting the concept of a united airway disease. Dupilumab, by blocking interleukin-4 and -13 receptors, can improve the clinical and functional parameters and life quality of comorbid patients with T2 diseases. AIM: To evaluate efficacy of anti-IL4R,13 therapy in patients with severe asthma with chronic inflammatory nasal diseases in real clinical practice. MATERIALS AND METHODS: The study of dupilumab efficacy was conducted by comparing related populations based on a regional register of patients with severe asthma and concomitant chronic inflammatory nasal diseases. Asthma control achievement and decrease in the rate of patients with uncontrolled asthma were assessed as primary endpoint. The need for bronchodilators and systemic glucocorticosteroids, number of asthma exacerbations, emergency calls and hospitalizations, AQLQ scores, level of peripheral blood eosinophils, and respiratory function were also assessed. Nasal symptoms were assessed using SNOT-22 and VAS. A subgroup analysis of ACT scores was performed depending on chronic inflammatory nasal disease phenotypes. RESULTS: Within 12 months of dupilumab therapy, ACT increased from 11 (Q1Q3: 713) to 20 (Q1Q3: 1824) points (p 0.001). The rate of patients with partially and fully controlled asthma increased from 0 to 57.9% (p 0.001). The need for bronchodilators decreased from 17.5 doses per week (Q1Q3: 5.824.5) to 1.0 (Q1Q3: 0.02.2) (p 0.001). Before the dupilumab therapy, 68.5% of the patients took systemic corticosteroids and, after 12 months, 10.5% of patients (p 0.001). The number of asthma exacerbations decreased from 2.191.83 (95% CI 1.283.11) to 0.220.55 (0.050.49) (p 0.001) and hospitalizations from 1.001.27 (95% CI 0.371.63) to 0.170.51 (95% CI 0.090.42) (p 0.001). AQLQ scores increased from 2.91 (Q1Q3: 2.433.86) to 5.89 points (Q1Q3: 4.706.58) (p 0.001). The volume of forced exhalation in 1 sec increased from 55.38%16.66% (95% CI 47.1063.67) to 81.5%19.14% (95% CI 71.9891.02) (p 0.001). SNOT-22 scores decreased from 4729 (95% CI 3461) to 2518 (95% CI 1734) points (p 0.001) and the VAS score from 72 (95% CI 68) to 42 (95% CI 35) (p 0.001). CONCLUSIONS: Dupilumab improved asthma and nasal symptoms control, improved quality of life and respiratory function, and reduce asthma exacerbations and hospitalizations. Patients with severe asthma and comorbid allergic rhinitis and chronic rhinosinusitis with polyps responded better to dupilumab therapy than patients with chronic rhinosinusitis without polyps.Keywords
This publication has 15 references indexed in Scilit:
- Chronic Rhinosinusitis with Nasal Polyps and AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody TherapyThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- EAACI Biologicals Guidelines—Recommendations for severe asthmaAllergy, 2020
- Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohortClinical & Experimental Allergy, 2020
- Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2020
- Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaNew England Journal of Medicine, 2018
- Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe AsthmaNew England Journal of Medicine, 2018
- Co‐morbidities in severe asthma: Clinical impact and managementRespirology, 2017
- Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trialThe Lancet, 2016
- Dupilumab in Persistent Asthma with Elevated Eosinophil LevelsNew England Journal of Medicine, 2013